COVID-19 vaccine trials
COVID-19 vaccine: Cuba hopeful about indigenous vaccine in Phase 3 trial

In previous trials, the Soberana 02 vaccine candidate generated antibody response in about 80% of the people who were administered two doses

Cuba working on a ‘People’s Vaccine’: the US and the world should get behind it

Amid growing accusations of vaccine hoarding by global north countries and patents blocking vaccine production, researcher and filmmaker Beth Geglia writes about the importance of supporting Cuba’s vaccines which will be available to all

Covaxin trials: What 81% “interim efficacy” means

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials.

Cuba’s anti-COVID vaccine candidate Soberana 02 begins phase III clinical trials

In this final and decisive phase of trials, the objective is to evaluate the efficacy, safety and immunogenicity of Soberana 02. If the vaccine produces fruitful results, Cuba will become the first country in the Latin American and the Caribbean region to develop its own vaccine

Cuba is one step closer to launching its own anti-COVID vaccines

Cuba is the only country in the Latin American and the Caribbean region that is working to develop its own vaccines against COVID-19. The country has four vaccine candidates. Two of them, Soberana 02 of the Finlay Vaccine Institute (IFV) and Abdala of the Center for Genetic Engineering and Biotechnology (CIGB), will begin the third phase of clinical trials in March

Bolivia approves emergency use of Russia’s Sputnik V vaccine

Bolivia hopes to vaccinate up to 20% of its population in the first quarter of this year. The health ministry has endorsed Russia’s Sputnik V and China’s CoronaVac vaccines against COVID-19

COVID-19 vaccine: Rich countries might gain, poor ones might suffer

As trials for vaccine candidates continue, the question of which countries will gain access to it has become pressing. Low-income countries are likely to suffer in this regard

COVID-19: Study suggests immunity against SARS-CoV-2 could last for six months

The study analyzed the immune memory against the virus in 185 patients who had recovered from COVID-19. These included patients who were asymptomatic and those who exhibited severe clinical symptoms

EU extends sanctions against Venezuela

The extension comes as the country continues to battle the COVID-19 pandemic, with Maduro securing 10 million Sputnik V vaccine doses.

Good news on vaccines but what about its delivery?

If we plan to vaccinate the entire Indian people, the states need to be involved in a big way, however, the Modi government has so far centralized all aspects of the management of the epidemic, treating it only as an administrative problem.

Vaccine distribution: Cold storage requirement for potential COVID-19 vaccine a major problem

Newsclick’s Prabir Purkayastha and immunologist Dr. Satyajit Rath discuss the challenges of taking a vaccine to the people in countries like India. They also look at the various vaccine candidates in contention

Even with vaccines, it is a long and rocky road to immunity

Even if the major economies can solve their own problems of procuring the vaccines by jumping the queue with money or captive production capacities, what about the rest of the world?

    × To Subscribe